372 related articles for article (PubMed ID: 31331016)
1. Recent Updates on Molecular Imaging Reporting and Data Systems (MI-RADS) for Theranostic Radiotracers-Navigating Pitfalls of SSTR- and PSMA-Targeted PET/CT.
Werner RA; Thackeray JT; Pomper MG; Bengel FM; Gorin MA; Derlin T; Rowe SP
J Clin Med; 2019 Jul; 8(7):. PubMed ID: 31331016
[TBL] [Abstract][Full Text] [Related]
2. Molecular imaging reporting and data systems (MI-RADS): a generalizable framework for targeted radiotracers with theranostic implications.
Werner RA; Bundschuh RA; Bundschuh L; Javadi MS; Higuchi T; Weich A; Sheikhbahaei S; Pienta KJ; Buck AK; Pomper MG; Gorin MA; Lapa C; Rowe SP
Ann Nucl Med; 2018 Oct; 32(8):512-522. PubMed ID: 30109562
[TBL] [Abstract][Full Text] [Related]
3. Validation of the standardization framework SSTR-RADS 1.0 for neuroendocrine tumors using the novel SSTR‑targeting peptide [
Ebner R; Lohse A; Fabritius MP; Rübenthaler J; Wängler C; Wängler B; Schirrmacher R; Völter F; Schmid HP; Unterrainer LM; Öcal O; Hinterberger A; Spitzweg C; Auernhammer CJ; Geyer T; Ricke J; Bartenstein P; Holzgreve A; Grawe F
Eur Radiol; 2024 May; ():. PubMed ID: 38769164
[TBL] [Abstract][Full Text] [Related]
4. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
5. Validation of the SSTR-RADS 1.0 for the structured interpretation of SSTR-PET/CT and treatment planning in neuroendocrine tumor (NET) patients.
Grawe F; Ebner R; Geyer T; Beyer L; Winkelmann M; Sheikh GT; Eschbach R; Schmid-Tannwald C; Cyran CC; Ricke J; Bartenstein P; Heimer MM; Faggioni L; Spitzweg C; Fabritius MP; Auernhammer CJ; Ruebenthaler J
Eur Radiol; 2023 May; 33(5):3416-3424. PubMed ID: 36964768
[TBL] [Abstract][Full Text] [Related]
6. Reliability and practicability of PSMA-RADS 1.0 for structured reporting of PSMA-PET/CT scans in prostate cancer patients.
Grawe F; Blom F; Winkelmann M; Burgard C; Schmid-Tannwald C; Unterrainer LM; Sheikh GT; Pfitzinger PL; Kazmierczak P; Cyran CC; Ricke J; Stief CG; Bartenstein P; Ruebenthaler J; Fabritius MP; Geyer T
Eur Radiol; 2024 Feb; 34(2):1157-1166. PubMed ID: 37624414
[TBL] [Abstract][Full Text] [Related]
7. High Interobserver Agreement for the Standardized Reporting System SSTR-RADS 1.0 on Somatostatin Receptor PET/CT.
Werner RA; Derlin T; Rowe SP; Bundschuh L; Sheikh GT; Pomper MG; Schulz S; Higuchi T; Buck AK; Bengel FM; Bundschuh RA; Lapa C
J Nucl Med; 2021 Apr; 62(4):514-520. PubMed ID: 32859702
[TBL] [Abstract][Full Text] [Related]
8. The significance of equivocal bone findings in staging PSMA imaging in the preoperative setting: validation of the PSMA-RADS version 1.0.
Kuten J; Dekalo S; Mintz I; Yossepowitch O; Mano R; Even-Sapir E
EJNMMI Res; 2021 Jan; 11(1):3. PubMed ID: 33409930
[TBL] [Abstract][Full Text] [Related]
9. Follow-up of Lesions with Equivocal Radiotracer Uptake on PSMA-Targeted PET in Patients with Prostate Cancer: Predictive Values of the PSMA-RADS-3A and PSMA-RADS-3B Categories.
Yin Y; Werner RA; Higuchi T; Lapa C; Pienta KJ; Pomper MG; Gorin MA; Rowe SP
J Nucl Med; 2019 Apr; 60(4):511-516. PubMed ID: 30190303
[TBL] [Abstract][Full Text] [Related]
10. Training on Reporting and Data System (RADS) for Somatostatin-Receptor Targeted Molecular Imaging Can Reduce the Test Anxiety of Inexperienced Readers.
Weich A; Higuchi T; Bundschuh RA; Lapa C; Serfling SE; Rowe SP; Pomper MG; Herrmann K; Buck AK; Derlin T; Werner RA
Mol Imaging Biol; 2022 Aug; 24(4):631-640. PubMed ID: 35233654
[TBL] [Abstract][Full Text] [Related]
11. Protocol for the PRIMARY clinical trial, a prospective, multicentre, cross-sectional study of the additive diagnostic value of gallium-68 prostate-specific membrane antigen positron-emission tomography/computed tomography to multiparametric magnetic resonance imaging in the diagnostic setting for men being investigated for prostate cancer.
Amin A; Blazevski A; Thompson J; Scheltema MJ; Hofman MS; Murphy D; Lawrentschuk N; Sathianathen N; Kapoor J; Woo HH; Chalasani V; Rasiah K; van Leeuwen PJ; Tang R; Cusick T; Stricker P; Emmett L
BJU Int; 2020 Apr; 125(4):515-524. PubMed ID: 31957122
[TBL] [Abstract][Full Text] [Related]
12. Changing Threshold-Based Segmentation Has No Relevant Impact on Semi-Quantification in the Context of Structured Reporting for PSMA-PET/CT.
Mihatsch PW; Beissert M; Pomper MG; Bley TA; Seitz AK; Kübler H; Buck AK; Rowe SP; Serfling SE; Hartrampf PE; Werner RA
Cancers (Basel); 2022 Jan; 14(2):. PubMed ID: 35053434
[TBL] [Abstract][Full Text] [Related]
13. Prostate-specific Membrane Antigen Reporting and Data System Version 2.0.
Werner RA; Hartrampf PE; Fendler WP; Serfling SE; Derlin T; Higuchi T; Pienta KJ; Gafita A; Hope TA; Pomper MG; Eiber M; Gorin MA; Rowe SP
Eur Urol; 2023 Nov; 84(5):491-502. PubMed ID: 37414701
[TBL] [Abstract][Full Text] [Related]
14. Effect of Point-Spread Function Reconstruction for Indeterminate PSMA-RADS-3A Lesions on PSMA-Targeted PET Imaging of Men with Prostate Cancer.
Khatri W; Chung HW; Werner RA; Leal JP; Pienta KJ; Lodge MA; Gorin MA; Pomper MG; Rowe SP
Diagnostics (Basel); 2021 Apr; 11(4):. PubMed ID: 33917238
[TBL] [Abstract][Full Text] [Related]
15. Interobserver Agreement for the Standardized Reporting System PSMA-RADS 1.0 on
Werner RA; Bundschuh RA; Bundschuh L; Javadi MS; Leal JP; Higuchi T; Pienta KJ; Buck AK; Pomper MG; Gorin MA; Lapa C; Rowe SP
J Nucl Med; 2018 Dec; 59(12):1857-1864. PubMed ID: 30190304
[TBL] [Abstract][Full Text] [Related]
16. The theranostic promise for Neuroendocrine Tumors in the late 2010s - Where do we stand, where do we go?
Werner RA; Weich A; Kircher M; Solnes LB; Javadi MS; Higuchi T; Buck AK; Pomper MG; Rowe SP; Lapa C
Theranostics; 2018; 8(22):6088-6100. PubMed ID: 30613284
[TBL] [Abstract][Full Text] [Related]
17. SSTR-RADS Version 1.0 as a Reporting System for SSTR PET Imaging and Selection of Potential PRRT Candidates: A Proposed Standardization Framework.
Werner RA; Solnes LB; Javadi MS; Weich A; Gorin MA; Pienta KJ; Higuchi T; Buck AK; Pomper MG; Rowe SP; Lapa C
J Nucl Med; 2018 Jul; 59(7):1085-1091. PubMed ID: 29572257
[TBL] [Abstract][Full Text] [Related]
18. Glu-Ureido-Based Inhibitors of Prostate-Specific Membrane Antigen: Lessons Learned During the Development of a Novel Class of Low-Molecular-Weight Theranostic Radiotracers.
Kopka K; Benešová M; Bařinka C; Haberkorn U; Babich J
J Nucl Med; 2017 Sep; 58(Suppl 2):17S-26S. PubMed ID: 28864607
[TBL] [Abstract][Full Text] [Related]
19. Prostate-specific Membrane Antigen PET: Clinical Utility in Prostate Cancer, Normal Patterns, Pearls, and Pitfalls.
Hofman MS; Hicks RJ; Maurer T; Eiber M
Radiographics; 2018; 38(1):200-217. PubMed ID: 29320333
[TBL] [Abstract][Full Text] [Related]
20. Pearls and pitfalls in clinical interpretation of prostate-specific membrane antigen (PSMA)-targeted PET imaging.
Sheikhbahaei S; Afshar-Oromieh A; Eiber M; Solnes LB; Javadi MS; Ross AE; Pienta KJ; Allaf ME; Haberkorn U; Pomper MG; Gorin MA; Rowe SP
Eur J Nucl Med Mol Imaging; 2017 Nov; 44(12):2117-2136. PubMed ID: 28765998
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
